Andrea Micheli

Andrea Micheli

Auto-generated profile, based on publicly available information

Andrea Micheli

Scientific Consultant for Scientific Direction and Descriptive Studies and Health Planning Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2008 in The Lancet Oncology
Verified
Journal Article
Open access
MCMichel P Coleman
Michel P Coleman
MQManuela Quaresma
Manuela Quaresma
FBFranco Berrino
Franco Berrino
JLJean-Michel Lutz
Jean-Michel Lutz
RARoberta De Angelis
Roberta De Angelis
CGCONCORD Working Group
CONCORD Working Group
Cancer survival varies widely between countries. The CONCORD study provides survival estimates for 1.9 million adults (aged 15-99 years) diagnosed with a first, primary, invasive cancer of the breast (women), colon, rectum, or prostate during 1990-94 and followed up to 1999, by use of individual tumour records from 101 population-based cancer registries in 31 countries on five continents. This is, to our knowledge, the first worldwide analysis of cancer survival, with standard quality-control procedures and identical analytic methods for all datasets. To compensate for wide international differences in general population (background) mortality by age, sex, country, region, calendar period, and (in the USA) ethnic origin, we estimated relative survival, the ratio of survival noted in the patients with cancer, and the survival that would have been expected had they been subject only to the background mortality rates. 2800 life tables were constructed. Survival estimates were also adjusted for differences in the age structure of populations of patients with cancer. Global variation in cancer survival was very wide. 5-year relative survival for breast, colorectal, and prostate cancer was generally higher in North America, Australia, Japan, and northern, western, and southern Europe, and lower in Algeria, Brazil, and eastern Europe. CONCORD has provided the first opportunity to estimate cancer survival in 11 states in USA covered by the National Program of Cancer Registries (NPCR), and the study covers 42% of the US population, four-fold more than previously available. Cancer survival in black men and women was systematically and substantially lower than in white men and women in all 16 states and six metropolitan areas included. Relative survival for all ethnicities combined was 2-4% lower in states covered by NPCR than in areas covered by the Surveillance Epidemiology and End Results (SEER) Program. Age-standardised relative survival by use of the appropriate race-specific and state-specific life tables was up to 2% lower for breast cancer and up to 5% lower for prostate cancer than with the census-derived national life tables used by the SEER Program. These differences in population coverage and analytical method have both contributed to the survival deficit noted between Europe and the USA, from which only SEER data have been available until now. Until now, direct comparisons of cancer survival between high-income and low-income countries have not generally been available. The information provided here might therefore be a useful stimulus for change. The findings should eventually facilitate joint assessment of international trends in incidence, survival, and mortality as indicators of cancer control.

1 September 2007 in The Lancet Oncology
Verified
Journal Article
Closed access
AVArduino Verdecchia
Arduino Verdecchia
SFSilvia Francisci
Silvia Francisci
HBHermann Brenner
Hermann Brenner
Gemma GattaGemma Gatta
Gemma Gatta
AMAndrea Micheli
Andrea Micheli
IKIan Kunkler
Ian Kunkler

1 December 2003 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
MSM. Sant
M. Sant
TAT. Aareleid
T. Aareleid
FBF. Berrino
F. Berrino
MLM. Bielska Lasota
M. Bielska Lasota
PCP. M. Carli
P. M. Carli
DLD. Lisi
D. Lisi
1Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy; 2Institute of Experimental and Clinical Medicine and Estonian Cancer Registry, Tallinn,

6 March 1996 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
FBFranco Berrino
Franco Berrino
PMPaola Muti
Paola Muti
AMAndrea Micheli
Andrea Micheli
GBGianfranco Bolelli
Gianfranco Bolelli
VKVittorio Krogh
Vittorio Krogh
GSGiorgio Secreto
Giorgio Secreto
High levels of androgens and estrogens have been reported to be associated with breast cancer. However, the multiplicity of factors that influence hormone levels and methodologic issues complicate the study of the relationship between steroid sex hormones and breast cancer. Using an improved study design, we assessed prospectively the relationship between the principal steroid sex hormones in serum and the subsequent occurrence of invasive breast cancer in postmenopausal women. Four thousand fifty-three healthy post-menopausal women, aged 40–69 years, were enrolled from June 1987 through June 1992 in a prospective investigation of hormones and diet in the etiology of breast tumors (ORDET study) as part of a larger volunteer cohort of 10 788 premenopausal and postmenopausal women from Varese Province, northern Italy. At recruitment, blood samples were taken between 8:00 AM and 9:30 AM (after overnight fasting), and sera were preserved in −80 °C freezers. Women who had received hormone treatment in the 3 months prior to enrollment, who had a bilateral ovariectomy, or who had a history of cancer or liver disease were not recruited. Twenty-five women in the final eligible cohort of 4040 postmenopausal women developed histologically confirmed, invasive breast cancer during the first 3.5 years of follow-up for the cohort (13 537 woman-years). For each case subject, four control subjects were randomly chosen after matching for factors possibly affecting hormone preservation in serum. One case subject and eight control subjects were excluded because premenopausal hormonal patterns were found; thus, after also excluding the four control subjects matched to the ineligible case subject, we included 24 case and 88 control subjects. In the spring of 1994, stored sera of case and control subjects were assayed in a blinded manner for dehydroepiandrosterone sulfate and estradiol (E 2 ) by in-house radioimmunoassay and for total and free testosterone and sex hormonebinding globulin by commercially available nonextraction iodination kits. Mean differences in risk factors were tested by analysis of variance for paired data. Relative risks (RRs) were estimated by conditional logistic regression analysis. All P values resulted from two-sided tests. Age-adjusted mean values of total testosterone, free testosterone, and E 2 were significantly higher in case subjects than in control subjects: total testosterone, 0.34 ng/mL versus 0.25 ng/mL ( P <.001); free testosterone, 1.07 pg/mL versus 0.77 pg/mL ( P = .006); and E 2 , 25 pg/mL versus 22 pg/mL ( P = .027). Age-adjusted RRs for breast cancer in increasing tertiles were as follows: for total testosterone, 1.0, 4.8, and 7.0 ( P for trend = .026); for free testosterone, 1.0, 1.8, and 5.7 ( P for trend = .005); and for total E 2 , 1.0, 7.1, and 5.5 ( P for trend = .128). This prospective study provides further evidence in support of the already established association between elevated estrogen levels and breast cancer. Even more importantly, it provides new evidence that high serum testosterone levels precede breast cancer occurrence. [J Natl Cancer Inst 1996;88:291–6]

1 February 2004 in European Journal of Endocrinology
Verified
Journal Article
Closed access
ALA Lukanova
A Lukanova
ELE Lundin
E Lundin
AZA Zeleniuch-Jacquotte
A Zeleniuch-Jacquotte
PMP Muti
P Muti
AMA Mure
A Mure
RKR Kaaks
R Kaaks
OBJECTIVE: Excess weight has been associated with increased risk of cancer at several organ sites. In part, this effect may be modulated through alterations in the metabolism of sex steroids and IGF-I related peptides. The objectives of the study were to examine the association of body mass index (BMI) with circulating androgens (testosterone, androstenedione and dehydroepiandrosterone sulfate (DHEAS)), estrogens (estrone and estradiol), sex hormone-binding globulin (SHBG), IGF-I and IGF-binding protein (IGFBP)-3, and the relationship between sex steroids, IGF-I and IGFBP-3. DESIGN AND METHODS: A cross-sectional analysis was performed using hormonal and questionnaire data of 620 healthy women (177 pre- and 443 post-menopausal). The laboratory measurements of the hormones of interest were available from two previous case-control studies on endogenous hormones and cancer risk. RESULTS: In the pre-menopausal group, BMI was not related to androgens and IGF-I. In the post-menopausal group, estrogens, testosterone and androstenedione increased with increasing BMI. The association with IGF-I was non-linear, with the highest mean concentrations observed in women with BMI between 24 and 25. In both pre- and post-menopausal subjects, IGFBP-3 did not vary across BMI categories and SHBG decreased with increasing BMI. As for the correlations between peptide and steroid hormones, in the post-menopausal group, IGF-I was positively related to androgens, inversely correlated with SHBG, and not correlated with estrogens. In the pre-menopausal group, similar but weaker correlations between IGF-I and androgens were observed. CONCLUSIONS: These observations offer evidence that obesity may influence the levels of endogenous sex-steroid and IGF-related hormones in the circulation, especially after menopause. Circulating IGF-I, androgens and SHBG appear to be related to each other in post-menopausal women.

1 April 2009 in European Journal of Cancer
Verified
Journal Article
Closed access
AMA. Micheli
A. Micheli
RCR. Ciampichini
R. Ciampichini
WOW. Oberaigner
W. Oberaigner
LCL. Ciccolallo
L. Ciccolallo
EVEsther De Vries
Esther De Vries
RAR. De Angelis
R. De Angelis